OCULAR THERAPEUTIX, INC (OCUL) Gross Margin
- Gross margin · 12 months: Value (m); Formula and calculation Gross profit / revenue. Period ending 2026-06-30..
Gross margin
Overview →Financial period ending 2026-06-30; current quote (m). Amounts retain their stated periods and units.
| Metric | Value | Formula and calculation |
|---|---|---|
| Gross margin · 12 months | (m) | Gross profit / revenue. Period ending 2026-06-30. Calculation unavailable: missing inputs remain (m). |
Calculation inputs
| Input | Amount with unit | Raw financial data |
|---|---|---|
| Gross profit | (m) | |
| Revenue | 52.05M USD | Revenue from Contract with Customer, Excluding Assessed Tax |
| Cost of products and services | 6.71M USD | Cost of Goods and Services Sold |
Calculated history
Changes compare with the next older row (previous quarter), unless explicitly labeled otherwise. Rolling 12-month growth compares two successive quarter-end rolling totals; it is not year-over-year growth.
| Period ending | Gross profit (USD) | Revenue (USD) | Cost of products and services (USD) | Gross margin |
|---|---|---|---|---|
| 2026-06-30 | (m) | $52.05M | $6.71M | (m) |
| 2026-03-31 | (m) | $52.04M | $6.64M | (m) |
| 2025-12-31 | (m) | $51.95M | $6.57M | (m) |
| 2025-09-30 | (m) | $55.78M | $6.21M | (m) |
| 2025-06-30 | (m) | $56.66M | $6.00M | (m) |
| 2025-03-31 | (m) | $59.65M | $5.56M | (m) |
| 2024-12-31 | (m) | $63.72M | $5.63M | (m) |
| 2024-09-30 | (m) | $61.44M | $5.78M | (m) |
| 2024-06-30 | (m) | $61.10M | $5.60M | (m) |
| 2024-03-31 | (m) | $59.84M | $5.39M | (m) |
| 2023-12-31 | (m) | $58.44M | $5.28M | (m) |
| 2023-09-30 | (m) | $57.72M | $4.91M | (m) |
| 2023-06-30 | (m) | $54.60M | $4.60M | (m) |
| 2023-03-31 | (m) | $51.68M | $4.45M | (m) |
| 2022-12-31 | (m) | $51.49M | $4.54M | (m) |
| 2022-09-30 | (m) | $49.73M | $4.64M | (m) |
| 2022-06-30 | (m) | $49.91M | $4.87M | (m) |
| 2022-03-31 | (m) | $49.37M | $4.81M | (m) |
| 2021-12-31 | (m) | $43.52M | $4.41M | (m) |
| 2021-09-30 | (m) | $38.56M | $3.98M | (m) |
| 2021-06-30 | (m) | $32.29M | $3.12M | (m) |
| 2021-03-31 | (m) | $22.14M | $2.16M | (m) |
| 2020-12-31 | (m) | $17.40M | $2.08M | (m) |
| 2020-09-30 | (m) | $12.31M | $2.24M | (m) |
| 2020-06-30 | (m) | $7.26M | $2.60M | (m) |
| 2020-03-31 | (m) | $6.34M | $3.02M | (m) |
| 2019-12-31 | (m) | $4.23M | $2.33M | (m) |
| 2019-09-30 | (m) | $2.48M | (m) | (m) |
| 2019-06-30 | (m) | $2.14M | (m) | (m) |
| 2019-03-31 | (m) | $2.14M | (m) | (m) |
| 2018-12-31 | (m) | $1.99M | (m) | (m) |
| 2018-09-30 | (m) | $1.97M | (m) | (m) |
| 2018-06-30 | (m) | $2.00M | (m) | (m) |
| 2018-03-31 | (m) | $1.79M | (m) | (m) |
| 2017-12-31 | (m) | $1.92M | (m) | (m) |
| 2017-09-30 | (m) | $1.95M | (m) | (m) |
| 2017-06-30 | (m) | $1.90M | (m) | (m) |
| 2017-03-31 | (m) | $1.90M | (m) | (m) |
| 2016-12-31 | (m) | $1.89M | (m) | (m) |
| 2016-09-30 | (m) | $1.81M | (m) | (m) |
| 2016-06-30 | (m) | $1.76M | (m) | (m) |
| 2016-03-31 | (m) | $1.78M | (m) | (m) |
| 2015-12-31 | (m) | $1.75M | (m) | (m) |
| 2015-09-30 | (m) | $1.82M | (m) | (m) |
| 2015-06-30 | (m) | $1.53M | (m) | (m) |
| 2015-03-31 | (m) | $1.17M | (m) | (m) |
| 2014-12-31 | (m) | $772.00K | (m) | (m) |
| 2014-09-30 | (m) | (m) | (m) | (m) |
| 2014-06-30 | (m) | (m) | (m) | (m) |
| 2014-03-31 | (m) | (m) | (m) | (m) |
| 2012-12-31 | (m) | $10.00K | (m) | (m) |
(m) means missing inputs. Historical market-based ratios use the saved close on or immediately before period ending and that period’s reported shares; current quotes are not substituted. Five-year projections repeat historical CAGR, not analyst forecasts.
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Prestige Consumer Healthcare Inc. (PBH) | United States | $2.163B | 13.03 |
| Bausch Health Companies Inc. (BHC) | $2.113B | -1.68 | |
| Aurinia Pharmaceuticals Inc. (AUPH) | $2.207B | 7.18 | |
| Braveheart Bio, Inc. (BRVE) | United States | $2.106B | |
| PALVELLA THERAPEUTICS, INC. (PVLA) | United States | $2.105B | -35.55 |
| Trevi Therapeutics, Inc. (TRVI) | United States | $2.091B | -51.93 |
| Zai Lab Ltd (ZLAB) | $2.241B | -113.34 | |
| Generate Biomedicines, Inc. (GENB) | United States | $2.052B | |
| PERRIGO Co plc (PRGO) | Ireland | $2.038B | -0.79 |
| NEKTAR THERAPEUTICS (NKTR) | United States | $2.026B | -9.05 |